These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894 [TBL] [Abstract][Full Text] [Related]
23. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Brignola C; Iannone P; Pasquali S; Campieri M; Gionchetti P; Belluzzi A; Basso O; Miglioli M; Barbara L Dig Dis Sci; 1992 Jan; 37(1):29-32. PubMed ID: 1728527 [TBL] [Abstract][Full Text] [Related]
24. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Mahmud N; Kamm MA; Dupas JL; Jewell DP; O'Morain CA; Weir DG; Kelleher D Gut; 2001 Oct; 49(4):552-6. PubMed ID: 11559654 [TBL] [Abstract][Full Text] [Related]
25. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827 [TBL] [Abstract][Full Text] [Related]
26. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877 [TBL] [Abstract][Full Text] [Related]
27. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827 [TBL] [Abstract][Full Text] [Related]
28. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)]. Maier K; Fischer C; Klotz U; Heinkel K Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426 [TBL] [Abstract][Full Text] [Related]
29. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Singleton JW; Hanauer S; Robinson M Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281 [TBL] [Abstract][Full Text] [Related]
30. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Hanauer S Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400 [TBL] [Abstract][Full Text] [Related]
31. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191 [TBL] [Abstract][Full Text] [Related]
32. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Gordon M; Naidoo K; Thomas AG; Akobeng AK Cochrane Database Syst Rev; 2011 Jan; (1):CD008414. PubMed ID: 21249709 [TBL] [Abstract][Full Text] [Related]
33. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR; Mays DA Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Messori A; Brignola C; Trallori G; Rampazzo R; Bardazzi G; Belloli C; d'Albasio G; De Simone G; Martini N Am J Gastroenterol; 1994 May; 89(5):692-8. PubMed ID: 8172139 [TBL] [Abstract][Full Text] [Related]
35. Treatment of Crohn's disease with 5-ASA. Katz J Am J Gastroenterol; 1993 Sep; 88(9):1315-7. PubMed ID: 8362823 [No Abstract] [Full Text] [Related]
36. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease]. Bayerdörffer E; Bock H Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251 [TBL] [Abstract][Full Text] [Related]
37. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Brignola C; Cottone M; Pera A; Ardizzone S; Scribano ML; De Franchis R; D'Arienzo A; D'Albasio G; Pennestri D Gastroenterology; 1995 Feb; 108(2):345-9. PubMed ID: 7835575 [TBL] [Abstract][Full Text] [Related]
38. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group. Dig Dis Sci; 1987 Jun; 32(6):598-602. PubMed ID: 2882966 [TBL] [Abstract][Full Text] [Related]
39. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy]. Freund U; Schölmerich J; Siems H; Kluge F; Schäfer HE; Wannenmacher M Strahlenther Onkol; 1987 Oct; 163(10):678-80. PubMed ID: 3313776 [TBL] [Abstract][Full Text] [Related]
40. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Robinson MG Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]